CL2023001670A1 - Formulación de proteína de fusión con dominio extracelular de subunidad alfa del receptor ige fc - Google Patents

Formulación de proteína de fusión con dominio extracelular de subunidad alfa del receptor ige fc

Info

Publication number
CL2023001670A1
CL2023001670A1 CL2023001670A CL2023001670A CL2023001670A1 CL 2023001670 A1 CL2023001670 A1 CL 2023001670A1 CL 2023001670 A CL2023001670 A CL 2023001670A CL 2023001670 A CL2023001670 A CL 2023001670A CL 2023001670 A1 CL2023001670 A1 CL 2023001670A1
Authority
CL
Chile
Prior art keywords
ige
receptor
fusion protein
formulation
alpha subunit
Prior art date
Application number
CL2023001670A
Other languages
English (en)
Inventor
Ho Jang Myung
Cho Young-Gyu
Kwon Soontak
Original Assignee
Gi Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Innovation Inc filed Critical Gi Innovation Inc
Publication of CL2023001670A1 publication Critical patent/CL2023001670A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente patente de invención está relacionada principalmente con una formulación de proteína de fusión que comprende el dominio de la subunidad alfa del receptor extracelular IgE Fc.
CL2023001670A 2021-03-09 2023-06-08 Formulación de proteína de fusión con dominio extracelular de subunidad alfa del receptor ige fc CL2023001670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20210030501 2021-03-09

Publications (1)

Publication Number Publication Date
CL2023001670A1 true CL2023001670A1 (es) 2023-11-24

Family

ID=83227989

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001670A CL2023001670A1 (es) 2021-03-09 2023-06-08 Formulación de proteína de fusión con dominio extracelular de subunidad alfa del receptor ige fc

Country Status (13)

Country Link
US (1) US20240148829A1 (es)
EP (1) EP4306103A1 (es)
JP (1) JP2024509937A (es)
KR (1) KR20220126654A (es)
CN (1) CN116963721A (es)
AU (1) AU2022232566A1 (es)
CA (1) CA3211978A1 (es)
CL (1) CL2023001670A1 (es)
IL (1) IL305512A (es)
MX (1) MX2023010457A (es)
PE (1) PE20240120A1 (es)
TW (1) TW202302138A (es)
WO (1) WO2022191550A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2415604T3 (es) 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
EP2331578B1 (en) 2008-09-17 2014-06-04 Xencor, Inc. Novel compositions and methods for treating ige-mediated disorders
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
WO2019135666A1 (ko) * 2018-01-08 2019-07-11 주식회사 프로젠 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물
SG11202005858WA (en) 2018-01-08 2020-07-29 Gi Innovation Inc Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same
KR20200125590A (ko) * 2018-01-26 2020-11-04 제넨테크, 인크. 조성물 및 사용 방법
EP3876978A4 (en) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
IL305512A (en) 2023-10-01
AU2022232566A1 (en) 2023-08-03
JP2024509937A (ja) 2024-03-05
EP4306103A1 (en) 2024-01-17
US20240148829A1 (en) 2024-05-09
CA3211978A1 (en) 2022-09-15
CN116963721A (zh) 2023-10-27
MX2023010457A (es) 2023-09-14
PE20240120A1 (es) 2024-01-22
AU2022232566A9 (en) 2024-05-16
KR20220126654A (ko) 2022-09-16
WO2022191550A1 (ko) 2022-09-15
TW202302138A (zh) 2023-01-16

Similar Documents

Publication Publication Date Title
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
ECSP17073650A (es) Proteínas de fusión
CO2020013246A2 (es) Proteínas de fusión interleucina-2/receptor alfa de interleucina-2 y métodos de uso
CL2018000270A1 (es) Constructos de anticuerpo para cd70 y cd3.
CL2017000111A1 (es) Moléculas con especificidad para cd45 y cd79
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CO2020008752A2 (es) Variantes de dominio de fc de igg humana con función efectora mejorada
CL2016000249A1 (es) Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
CL2018002045A1 (es) Conjugado de enzimas terapéuticas
CO2019005909A2 (es) Anticuerpos y polipéptidos dirigidos contra cd127
GT200900268A (es) Polipeptidos de factor vii modificados y usos de los mismos .
TWD191630S (zh) Reaction tube
CL2021001685A1 (es) Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar
CL2007000526A1 (es) Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende.
BR112018074437A2 (pt) cepa de bacillus licheniformis com atividade probiótica
TWD197760S (zh) 包裝用瓶
PE20141479A1 (es) Senuelos humanos notch1
UY32597A (es) Composicion limpiadora liquida con peliculas
CL2023001670A1 (es) Formulación de proteína de fusión con dominio extracelular de subunidad alfa del receptor ige fc
CU24630B1 (es) Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
CO2022003829A2 (es) Moduladores de receptor alfa relacionado con estrógenos (errα)
CO2021017619A2 (es) Moduladores del receptor alfa relacionado con estrógeno (errα)
PE20210108A1 (es) Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma
TWD192802S (zh) Bottle (1)